

Regular Meeting of the Santa Clara County Health Authority Provider Advisory Council (PAC)

Thursday, February 2, 2017 12:15 PM – 1:45 PM 210 E. Hacienda Avenue Campbell, CA 95008

AGENDA

1.	Roll Call	Dr. Padua, Chair	12:15	5 min.
2.	Meeting Minutes Review minutes from October 6, 2016 - Regular Meeting. Possible Action: Approve minutes.	Dr. Padua, Chair	12:20	5 min.
3.	Public Comment Members of the public may speak to any item not on the agenda; 2 minutes per speaker. The Committee reserves the right to limit the duration of public comment period to 30 minutes.	Dr. Padua, Chair	12:25	5 min.
4.	Committee Membership and Charter a. Resignation of Dr. Stephen Ho, CMO, Excel	Dr. Padua, Chair	12:30	10 min.
	 b. Governing Board approval of charter c. Re-appointment of committee members 	Ms. Tomcala, CEO	12:40	5 min.
5.	Chief Executive Officer Discussion on membership and current topics.	Ms. Tomcala, CEO	12:45	15 min.
6.	Chief Medical Officer Discussion on CME and current topics.	Dr. Robertson, CMO	1:00	10 min.
7.	Case Management Discussion on palliative care.	Ms. Peterson, Manager Case Management	1:10	20 min.

8. Quality and Pharmacy
a. Update from P&T Committee on Epi Pen
recommendation from October meeting.
b. Discussion on Drug Report.

Pharmacy

Confidentiality, Conflict of Interest and Non-Discrimination
Statement

Ms. Liu,
Director of
Quality and
Pharmacy

1:30 10 min.

1:40 5 min

Possible Action: Sign statement for 2017

10. Adjournment Dr. Padua, Chair 1:45

Notice to the Public-Meeting Procedures

- Persons wishing to address the PAC on any item on the agenda are requested to advise the Recorder so that the Chairperson can call on them when the item comes up for discussion.
- The PAC may take other actions relating to the issues as may be determined following consideration of the matter and discussion of the possible action.
- In compliance with the Americans with Disabilities Act, those requiring accommodations in this meeting should notify Rita Zambrano 48 hours prior to the meeting at 408-874-1842.
- To obtain a copy of any supporting document that is available, contact Rita Zambrano at 408-874-1842. Agenda materials
 distributed less than 72 hours before a meeting can be inspected at the Santa Clara Family Health Plan offices at 210 E. Hacienda
 Avenue, Campbell.
- This agenda and meeting documents are available at www.scfhp.com



Regular Meeting of the Santa Clara County Health Authority Provider Advisory Council (PAC)

Thursday, October 06, 2016 12:15 PM – 1:45 PM 210 E. Hacienda Avenue Campbell, CA 95008

Minutes

Members present:

Thad Padua, M.D., Chair
Steve Church
Bridget Harrision, M.D.
Peter Nguyen 12:30
Sherri Sager
Dolly Goel, M.D.
Tuyen Ngo, M.D.
Melinda Golden (on behalf of Dave Mineta)

Members not present:

Jimmy Lin, M.D. Stephen Ho, M.D.

Staff present:

Christine Tomcala, Chief Executive Officer
Jeff Robertson, M.D., Chief Medical Officer
Jennifer Clements, Director of PNM
Sherry Holm, Behavioral Health Program Manager
Johanna Liu, Director of QI & RX
Lori Andersen, Operations Director, LTSS
Art Shaffer, Sr. Provider Services Representative
Claudio Graciano, Sr. Provider Services Representative
Caroline Alexander, Administrative Assistant
Tanya Nguyen, Director of Member Services
Jamie Enke, Health Services Project Manager
Andre Aguirre, QI Manager

Staff not present:

Irene Walsh, MLTSS Provider Services Representative Abby Baldovinos, Sr. Provider Services Representative Robyn Esparza, Administrative Assistant

1. Roll Call

Thad Padua, MD, Chairperson, called the meeting to order at 12:25 pm. Roll call was taken and a quorum was established.

2. Minutes Review and Approval

- a. Meeting minutes were reviewed. Dr. Padua asked the Committee if there were any additional questions or comments regarding the July 27, 2016, meeting minutes.
 - ✓ It was moved, seconded, and the July 27, 2016 meeting minutes were approved as presented.
- b. Kingstom Lum was recommended for appointment to the Committee.
 - ✓ It was moved, seconded, and the appointment of Kingston Lum to the Committee was approved.

3. Public Comment

There were no public comments.

4. Chief Executive Officer Update

Ms. Christine Tomcala, CEO, presented the September 2016 Membership Summary.

Ms. Tomcala noted the current enrollment is 280,380, with the majority of our membership in Medi-Cal:

Healthy Kids: 2,962
 Cal MediConnect: 7,909
 Medi-Cal: 269,402

Ms. Tomcala noted the following during Fiscal Year of July 2015 to June 2016:

- There was an increase in membership from a little over 260,000 members.
- Revenue increased by approximately 29.5%. Most of the growth was in the Seniors and Persons with Disabilities population (SPD), as well as the adult population.
- The Plan is looking at more outreach in the community which will involve working with providers regarding topics such as what Cal MediConnect has to offer and what Cal MediConnect is.

Committee encouraged providers to refer members for Consumer Advisory Committee.

Also, encourage referring members that are reflective of Medi-Cal population in the county (Seniors, Disabled).

Chief Medical Officer

Dr. Robertson presented an update on CME topics available to the group. The six different topics to choose from this year are as follows:

- Autoimmune Encephalitis
- Neurological Manifestations of Lyme Disease
- Population Health Science: A New Way to Think About Child Health
- Treatment and Prevention of Ischemic Stroke
- Neurodegenerative Disease
- Lower Extremity Injuries in the Child and Adolescent: Evaluation and Treatment
 - ✓ The committee unanimously voted for Population Health Science as the topic of most interest for a CME session.

Dr. Robertson presented an update on Medicare registration for providers. Committee advised that a notice was sent to providers in May regarding Medicare prescriber enrollment requirement. Starting February 1, 2017, claims for prescribers not enrolled in Medicare will temporarily be covered through the provisional fill policy. This will allow Cal MediConnect members to receive up to a 3 month fill for each of their medications. After this provisional fill, subsequent claims for the medication will be rejected at the point of sale if the prescriber is not actively enrolled in Medicare or opted-out.

SCFHP Strategic Plan 2016-2017

Ms. Tomcala presented the Strategic Plan for Fiscal Year July 2016 - June 2017, noting a lot of carryover from previous fiscal year.

Ms. Tomcala noted the following key points:

- Plan is working on building infrastructure.
- The top priority is compliance. Working on strengthening Fraud, Waste and Abuse program as part
 of increased compliance.
- Implementing new claims system for Medi-Cal population.
- Implementing QNXT for both Cal MediConnect and Medi-Cal products.
- Developing a reporting and analytics structure.
- Working on fostering membership growth and retention by developing and implementing Cal MediConnect and Medi-Cal retention activities.
- Initiating marketing and outreach program for Cal MediConnect by January 2017. Implement Model
 of Care for Cal MediConnect and SPD population by January 2017 as part of establishing complex
 care delivery expertise.
- As part of union contract, the Plan to convene a Compensation Committee, which will re-write all
 job descriptions and benchmark pay ranges by fourth Quarter of 2016.
- Achieve budgeted financial performance by achieving Fiscal Year 2016-2017 Net Surplus of \$11.7 million.

7. Provider Incentive Program

Dr. Robertson presented an overview of the Provider Incentive Program. Incentive is paid out to capitated Primary Care Physician groups as applicable. Provider groups receive incentive check based on performance measures, such as emergency admits, generic prescription rates etc. Program based on HEDIS scores, increase in access, and Quality of Care.

Medi-Cal Program to include the following five measures:

- All Cause Readmission
- Cervical Cancer Screening
- IHA (Initial Health Assessment)
- Access to Primary Care,
- Encounter Data

The Plan to expand to six or seven measures next year.

8. Quality and Pharmacy Update

Ms. Liu presented the third quarter drug report, noting the top drugs requested for prior authorization for Medi-Cal and Healthy Kids are epi-pens and insulin and the lidocaine patch for Cal MediConnect. Ms. Liu noted the top drug by cost for Medi-Cal and Healthy Kids was Hep C agents, followed by Humira and diabetes medications. For Cal MediConnec, the top drug by cost was Hep C agents, followed by diabetes and antipsychotic medications. No new trends to report from last quarter.

Ms. Sager recommended splitting out pharmacy costs by age on future reports.

9. Member Enrollment

Ms. Nguyen presented an overview of member enrollment and provider assignment process to the Committee.

10.	Access	and	Availability
-----	--------	-----	---------------------

Ms. Clements presented an update on contracts with Acupuncturists and an update on providers for End of Life Benefit. Plan is working on contracts with Acupuncturists, a few are working on credentialing. Redirecting to Medi-Cal Fee for Service providers as far as End of Life providers.

11. Meeting Calendar for 2017

Dr. Padua presented the 2017 meeting calendar to the committee.

✓ Committee approved continuing to meet on Thursday's.

12. Adjournment

It was moved, seconded, and approved to adjourn the meeting at 1:50pm.

✓ Next Meeting is scheduled for February 02, 2017.

Dr. Thad Padua, PAC Committee Chair	Date	



Santa Clara County Health Authority Provider Advisory Council Charter

Purpose

Pursuant to the Bylaws, the Governing Board shall establish a Provider Advisory Council whose members can provide expertise to the Santa Clara Family Health Plan (SCFHP) relative to their respective specialties. The Provider Advisory Council shall act as an advisory committee to assist SCFHP in creating and maintaining a system of care in accordance with the six C's of care -- Community, Collaboration, Coordination, Communication, Caring, and Compassion.

The Council's mission is to discuss regional or national issues regarding the relationships and interactions between provider, their patients and SCFHP. These issues include improving health care and clinical quality, improving communications, relations, and cooperation between providers and SCFHP, and clinical or regulatory matters that affect interactions between providers and SCFHP.

Members

The Provider Advisory Council shall have a sufficient number of members to provide necessary expertise and work effectively as a group. The Provider Advisory Council shall include contracted providers from a range of specialties as well as other representatives from the community including but not limited to representatives from contracted hospitals, Medical Directors from contracted IPAs, non-physician representatives who possess knowledge regarding the initiatives and issues facing the patient and provider community, and representation from the behavioral health community.

All Provider Advisory Council (PAC) members, including the Chairperson, shall be appointed by the SCFHP's Chief Executive Officer.

All PAC members, including the Chair, serve two-year terms which may be renewed at the discretion of the CEO, provided that the member is in compliance with the requirements set forth in this charter. Provider Advisory Council members shall annually sign a Confidentiality Agreement. Failure to sign the agreement or abide by the terms of the agreement shall result in removal from the Committee.

Meetings

Regular meetings of the Provider Advisory Council shall be scheduled quarterly.

Additional special meetings, or meeting cancellations, may occur as circumstances dictate. Special meetings may be held at any time and place as may be designated by the Chair, the Chief Executive Officer, or a majority of the members of the Committee.

Committee members must attend at least two meetings per year. Attendance may be in person or via teleconferencing. Teleconferencing shall be conducted pursuant to California Government Code section 54953(d). The presence of a majority of the Committee members shall constitute a quorum for the transaction of business.

The Committee may invite other individuals, such as members of management, auditors, or other technical experts to attend meetings and provide pertinent information relating to an agenda item, as necessary.

Meetings of the Provider Advisory Council shall be open and public pursuant to the Ralph M. Brown Act (Gov. Code § 54950 et seq.)

The Director of Provider Network Management is responsible for notifying members of the dates and times of meetings and preparing a record of the Council's meetings.

Responsibilities

The following responsibilities shall serve as a guide, with the understanding that the Committee may carry out additional functions as may be appropriate in light of changing business, regulatory, legal, or other conditions. The Committee shall also carry out any other responsibilities delegated to it by the Board from time to time.

- Address clinical and administrative topics that affect interactions between physicians/providers and SCFHP.
- Discuss regional, state, and national issues related to enhancing patient care.
- Provide input on health care services of SCFHP.
- Provide input on the coordination of services between networks of SCFHP.
- Improve communications, relations, and cooperation between physicians/providers and SCFHP.
- Provide expertise to SCFHP relative to a Committee member's area of practice.




Medi-Cal Membership by Age Group and Network January 2017

Age	SCFHP Direct	Valley Health Plan	Kaiser	Palo Alto Medical Foundation	Physician's Medical Group	Premier Care	Total	Percentage
								`
< 6 Years	1,668	16,287	4,106	725	8,423	1,339	32,548	12.14%
6 to 17	4,435	33,602	9,497	1,757	18,516	4,523	72,330	26.98%
18 to 34	3,958	35,468	5,668	1,254	8,701	3,417	58,466	21.81%
35 to 44	1,703	12,327	2,058	476	3,413	1,628	21,605	8.06%
45 to 54	1,622	13,815	1,909	647	4,102	2,532	24,627	9.19%
55 to 64	1,813	16,198	1,796	664	4,095	2,777	27,343	10.20%
65 to 74	5,310	7,941	789	521	1,023	319	15,903	5.93%
75 to 84	4,076	4,574	805	905	469	129	10,958	4.09%
>= 85 Years	1,971	1,421	410	426	76	30	4,334	1.62%
Total	26,556	141,633	27,038	7,375	48,818	16,694	268,114	100.00%
Percentage	9.90%	52.83%	10.08%	2.75%	18.21%	6.23%	100.00%	




Enrollment Summary as of January 2017


Membership by Line of Business




Medi-Cal Membership by Aid Category




Medi-Cal Membership by Age Group




Membership by Network



Medi-Cal Membership by Dual Status



Medi-Cal Membership by Language





Sant.a Clara Family Health Plan

The Spirit of Care

CME Event

Date:

03/23/17

Time:

6-8pm

Location:

Fiorillo's Restaurant in Santa Clara

638 El Camino Real, Santa Clara, CA 95050

Topic:

Lower Extremity Injuries in the Child and Adolescent:

Evaluation and Treatment

Presenter:

Meghan N. Imrie, MD

Clinical Assistant Professor of Orthopaedic Surgery Stanford

Learning Objectives:

- 1. Learn how to recognize and refer patients with slipped capital femoral epiphysis for prompt orthopedic treatment
- 2. Understand how common lower extremity in children and adolescents may defer than similar injuries in adults

Meghan N. Imrie, MD

Rady Children's Hospital San Diego 3030 Children's Way, MC 5062 San Diego, CA 92123-4282 (858) 966-4073 Home address: 390 Stratford Court #1 Del Mar, CA 92014 (650) 996-1985 mnimrie@yahoo.com

Education

9/99 - 6/03

University of California

Medical Doctorate

San Diego, California

9/94 - 6/98

Yale University

Bachelor of Science

New Haven, Connecticut

Chemistry

Post-degree Honors, Awards, and Professional Memberships

Passed ABOS Part I – Board Eligible

Stanford Orthopaedic Surgery Department Resident Research Award, 2008

Candidate Member, Pediatric Orthopaedic Society of North America

Team Member, Operation Rainbow 2007 - orthopaedic volunteer, Nicaragua

Recipient, Lena Sefton Clark Fellowship Award, Rady Children's Hospital, 2009

Work Experience

Stanford University

Lucille Packard Children's

Hospital Stanford, CA Assistant Clinical Professor, Pediatric Orthopaedics (9/09 -

present)

Children's Specialists of San

Diego

San Diego, CA

Pediatric Orthopaedic Fellow (8/08 - 7/09)

Stanford University Hospital

Palo Alto, CA

Orthopaedic Surgery Resident (6/03 – 7/08)

Structural Genomix

San Diego, CA

Summer Intern - Chemist (6/00 - 8/00)

Member of protein purification team in start-up biotech company.

Using variety of methods, worked with insoluble proteins as part

of biotechnology "assembly line."

UCSF Stanford Health Care

Orthopaedic Clinic

Palo Alto, CA

Medical Assistant (7/98 – 8/99)

Managed paperwork for the clinic. Roomed patients and assisted

doctors with injections, cast and suture removal.

Stanley H. Kaplan Education

Center

<u>Instructor</u> (1/99 – 4/99)

Taught Medical College Admissions Test preparation course.

San Jose, CA

Stanford Hospital

Palo Alto, CA

Operating Room Orderly (6/95 - 9/95, 6/96 - 9/96)

Assisted in daily operation of main operating rooms.

Meghan N. Imrie Page 2

Research and Publications

Children's Specialist's of San

Diego

San Diego, CA

Principal Contributor (8/08 - present)

With Dr. Scott Mubarak, evaluating the incidence of late dysplasia in children born breech with normal screening ultrasound. Presented 2009 *POSNA* meeting; nominated for Best Clinical

Paper, Accepted for presentation, 2010 AAOS meeting.

Principal Contributor (8/08 – present)

With Dr Peter Newton and Dr Burt Yaszay, evaluating the role of percent correction of idiopathic scoliosis with outcome. Accepted for presentation, 2009 NASS meeting, 2010 AAOS meeting.

Principal Contributor (8/08 - present)

With Dr. Henry Chambers, prospective study of outcomes in ACL reconstruction with and without postoperative CPM use. Ongoing

project.

Stanford Hospitals and

Clinics

Stanford, CA

Imrie M, Yao J. "The History of Distal Radius Fractures," Distal

Radius Fractures. Slutsky DJ, Osterman AL, eds, Elsevier,

Philadelphia, PA. 2008.

Lucille Packard Children's

Hospital

Stanford, CA

Principal Contributor (3/05 – present)

With Dr. Lawrence Rinsky, evaluating the clinical results of the Marchesi technique of pelvic fixation in neuromuscular scoliosis.

Submitted for presentation.

University of California

San Diego, CA

Principal Contributor (4/02 - 6/03)

With guidance of Dr. Jeffrey Smith of the Orthopaedic Trauma

Department, created an educational CD-ROM on acute

compartment syndrome.

Yale University

New Haven, CT

Research Assistant (9/98 – 6/98)

Assisted Dr. Ron Breaker in studying the enzymatic capabilities of nucleic acids using standard biochemical techniques. Developed new materials and methods to facilitate search for DNA and RNA

sequences of interest.

University of California

Berkeley, CA

Research Assistant (6/97 – 9/97)

Volunteered in the lab of Dr. Jack Kirsch studying the genetics and activities of several bacterial aminotransferase enzymes. Various techniques, such as transformation and ligation were used to construct a knockout bacterial strain to be used in future

to constituet a knockout oactorial strain to be a

enzyme investigation.


Extracurricular Activities/Interests

Yoga, ballet, modern dance

Gymnastics – 15 years competitive experience, including Division I collegiate gymnastics



State of California—Health and Human Services Agency Department of Health Care Services



DATE: XX, 2016

ALL PLAN LETTER 16-XXX

TO: ALL MEDI-CAL MANAGED CARE HEALTH PLANS

SUBJECT: PALLIATIVE CARE AND MEDI-CAL MANAGED CARE

PURPOSE:

The purpose of this All Plan Letter (APL) is to inform Medi-Cal managed care health plans (MCPs) of their obligation to provide palliative care to their beneficiaries pursuant to Senate Bill (SB) 1004 (Hernandez, chapter 574; Statues of 2014). The requirements discussed in this APL specifically apply to Medi-Cal managed care beneficiaries who are not Medicare – Medi-Cal dually-eligible beneficiaries.

BACKGROUND:

SB 1004 requires the Department of Health Care Services (DHCS) to establish standards and provide technical assistance to MCPs for the delivery of palliative care as codified in the Welfare and Institute Code (WIC) Section 14132.75. Palliative care consists of patient and family-centered care that optimizes quality of life by anticipating, preventing, and treating suffering. The provision of palliative care shall not result in the elimination or reduction of any covered benefits or services under the MCP contracts and shall not affect a beneficiary's eligibility to receive any services, including home health services, for which the beneficiary would have been eligible in the absence of receiving palliative care.

Hospice care is a Medi-Cal benefit that serves seriously ill beneficiaries consisting of interventions that focus primarily on pain and symptom management rather than cure or prolongation of life. To qualify for hospice care, a Medi-Cal beneficiary must have a life expectancy of six months or less. Further information regarding Medi-Cal hospice care can be found in APL 13-014.³

³ APL 13-014 can be found at:

http://www.dhcs.ca.gov/formsandpubs/Documents/MMCDAPLsandPolicyLetters/APL2013/APL13-014.pdf

¹SB 1004 (Hernandez, chapter 574, statues of 2014) is available at:

http://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill id=201320140SB1004

² WIC section 14132.75 is available at:

 $[\]underline{http://www.leginfo.ca.gov/cgi-bin/displaycode?section=wic\&group=14001-15000\&file=14131-14138.}$

Palliative care may be provided concurrently with curative care and does not require the beneficiary to have a life expectancy of six months or less. A beneficiary with a serious illness who is receiving palliative care may choose to transition to hospice care if he/she meets the hospice eligibility criteria. A beneficiary may not be concurrently enrolled in hospice care and palliative care.

A beneficiary under age 21 years may be eligible for palliative care concurrently with curative care through other existing programs such as Section 1915(c) Home and Community Based Services waiver known as Partners for Children (PFC) or Section 2302 of the Patient Protection and Affordable Care Act (ACA). Information regarding the concurrent care policy is available in APL 13-014⁴, California Children's Services Numbered Letter 06-1011⁵, and Managed Care Policy Letter 11-004⁶.⁷

POLICY:

DHCS' SB 1004 Palliative Care Policy⁸ specifies the types of palliative care MCPs must at a minimum authorize when medically necessary for a beneficiary who meets the minimum eligibility criteria. MCPs may either adopt DHCS' minimum eligibility criteria for palliative care, or submit a more liberal eligibility criteria to DHCS for approval.

I. Eligibility Criteria

DHCS' minimum eligibility criteria requires a beneficiary to meet all requirements for the general eligibility criteria and at least one of the four disease-specific eligibility requirements.

A. General Eligibility Criteria:

- 1. The beneficiary is likely to or has started to use the hospital or emergency department as a means to manage his/her late stage disease. This refers to unanticipated decompensation and does not include elective procedures.
- The beneficiary is in a late stage of illness, as defined in section B below, with appropriate documentation of continued decline in health status, and is not eligible for or declines hospice enrollment.

http://www.dhcs.ca.gov/formsandpubs/Documents/MMCDAPLsandPolicyLetters/APL2013/APL13-014.pdf

http://www.dhcs.ca.gov/formsandpubs/Documents/MMCDAPLsandPolicyLetters/PL2011/PL11-004.pdf

⁴ APL 13-014 can be found at:

⁵California Children's Services Numbered Letter 06-1011 can be found at http://www.dhcs.ca.gov/services/ccs/Documents/ccsnl061011.pdf

⁶ Managed Care Policy Letter 11-004 can be found at:

⁷ As concurrent care under Section 2302 of the ACA and the PFC waiver provide additional services and broader eligibility criteria for children than SB 1004, enrollment in SB 1004 and either Section 2302 concurrent care or the PFC waiver would result in redundant services. Children enrolled in either of those programs cannot enroll in SB 1004 palliative care.

⁸ DHCS' SB 1004 Medi-Cal Palliative Care Policy, dated September 1, 2016, can be found at: http://www.dhcs.ca.gov/provgovpart/Documents/SB1004PallCarePolicyDoc090116.pdf

- The beneficiary's death within a year would not be unexpected based on clinical status.
- The beneficiary has received appropriate patient-desired medical therapy, or for whom patient-desired medical therapy is no longer effective. Patient is not in reversible acute decompensation.
- 5. The beneficiary and, if applicable, the family/patient-designated support person, agrees to:
 - a. Attempt in-home, residential-based or outpatient disease management instead of first going to the emergency department; and
 - b. Participate in Advance Care Planning discussions.

B. Disease-Specific Eligibility Criteria:

- 1. Congestive Heart Failure (CHF): Must meet (a) and (b)
 - a. The beneficiary is hospitalized due to CHF as the primary diagnosis with no further invasive interventions planned OR meets criteria for New York Heart Association (NYHA) heart failure classification III or higher,⁹ AND
 - b. The beneficiary has an Ejection Fraction 30% for systolic failure OR significant co-morbidities.
- 2. Chronic Obstructive Pulmonary Disease (COPD): Must meet (a) or (b)
 - a. The beneficiary has a Forced Expiratory Volume (FEV)1 less than 35 % predicted AND 24-hour oxygen requirement of less than 3 liters (L) per minute OR
 - b. The begin lary has a 24-hour oxygen requirement of greater than or equal to 3L per minute.
- 3. Advanced Cancer: Must meet (a) and (b)
 - a. The beneficiary has a stage HI or IV solid organ cancer, lymphoma, or leukemia, AND
 - The beneficiary has a Karnofsky Performance Scale (KPS) score less than or equal to 70¹⁰ OR has failure of two lines of standard chemotherapy.
- 4. Liver Disease: Must meet (a) and (b) combined or (c) alone
 - a. The beneficiary has evidence of irreversible liver damage, serum albumin less than 3.0, and International Normalized Ratio (INR) greater than 1.3, AND

⁹ NYHA classifications are available at:

http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-

Failure UCM 306328 Article.jsp#.V-MZu9LH--o

^{10 &}quot;Performance Scales: Karnofsky and ECOG Scores," http://oncologypro.esmo.org/Guidelines-Practice/Practice-Tools/Performance-Scales

- The beneficiary has ascites, subacute bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, or recurrent esophageal varices OR
- The beneficiary has evidence of irreversible liver damage and has a Model for End Stage Liver Disease (MELD) score of greater than 19.¹¹

If a beneficiary continues to meet the above minimum eligibility criteria, he or she may continue to access both palliative care and curative care until the condition improves, stabilizes, or results in death. MCPs should periodically assess the beneficiary for changes in his/her condition or palliative care needs. MCPs may discontinue palliative care that is no longer medically necessary or reasonable.

II. Palliative Care

Effective April 1, 2017, when a beneficiary meets the minimum eligibility criteria for palliative care, MCPs must authorize palliative care without regard to age. Palliative care must include, at a minimum, the following eight services when medically necessary or reasonable for the palliation or management of a qualified serious illness and related conditions:

- Advance Care Planning: Advance care planning for beneficiaries enrolled in Medi-Cal palliative care under SB 1004 includes discussions between a physician or other qualified healthcare professional and a patient, family member, or surrogate in counseling and discussing advance directives, including Physicians Authorization for Life Sustaining Treatment (POLST) forms. Please refer to the section on Advanced Care Planning in the Provider Manual for further details.¹²
- 2. Palliative Care Assessment and Consultation: Palliative care assessment and consultation services may be provided at the same time as advance care planning, or in subsequent patient conversations. The palliative care consultation aims to collect both routine medical data and additional personal information not regularly included in a medical history or Health Risk Assessment. During an initial and/or subsequent palliative care consultation or assessment, topics may include, but are not limited to:
 - Treatment plans, including palliative care and curative care
 - Pain and medicine side effects
 - Emotional and social challenges

¹¹ MELD score calculator is available at: https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator

¹² Medi-Cal Provider Manual "Evaluation and Management (E&M)." Available at https://www.google.com/url?q=https://files.medi-cal.ca.gov/pubsdoco/publications/masters-mtp/part2/eval_m00o03.doc&sa=U&ved=0ahUKEwi1w7-e2KPPAhVV7GMKHclmCkUQFggEMAA&client=internal-uds-cse&usg=AFQjCNH1-XcVgZ-oocK-QzJhLYgZ1sMslA. Accessed September 22, 2016.

- Spiritual concerns
- Patient goals
- Advance directives, including POLST forms
- 3. Plan of Care: A plan of care should be developed with the engagement the beneficiary and/or his or her representative(s) in its design. If a beneficiary already has a plan of care, that plan should be updated to reflect any changes resulting from the palliative care consultation or advance care planning discussion. A beneficiary's plan of care must include all authorized palliative care, including but not limited to pain and symptom analogement and curative care.
- 4. Palliative Care Team: The palliative care team is a group of individuals who work together to meet the physical, medical, psychosocial, emotional and spiritual needs of beneficiaries and their families and are able to assist in identifying sources of pain and discomfort of the beneficiary. This may include problems with breathing, fatigue, depression, arxiety, insomnia, dewel or bladder, dyspnea, nausea, etc. The palliative care team will also address other issues such as medication services and allied health. The team members must provide all authorized palliative care. DHCS recommends that the palliative care team include but is not limited to, a doctor of medicine or osteopathy (Primary Care Provider if MD or DO), a registered nurse and/or nurse practitioner (Primary Care Provider if NP), a social worker, and a chaplain.
- 5. Care Coordination: A member of the palliative care team should provide coordination of care, ensure continuous assessment of the beneficiary's needs, and implement the plan of care.
- 6. Pain and Symptom Management: Adequate pain and symptom management is an essential component of palliative care. Prescription drugs, physical therapy and other medically necessary services may be needed to address beneficiary pain and other symptoms. The beneficiary's plan of care must include all services authorized for pain and symptom management.
- 7. Mental Health and Medical Social Services: Counseling services must be available to the beneficiary to assist in minimizing the stress and psychological problems that arise from a serious illness, related conditions, and the dying process. Counseling services must include, but are not limited to: psychotherapy, bereavement counseling, medical social services, and discharge planning as appropriate. Provision of mental health and medical social services shall not duplicate specialty mental health services (SMHS) provided by county Mental Health Plans (MHPs) and does not change the

MCP's responsibilities for referring to, and coordinating with, county MHPs as delineated in APL 13-021.¹³

8. Chaplain Services: MCPs must provide access to chaplain services, when reasonable, as part of the palliative care team. Chaplain services provided as palliative care are not reimbursable through the Medi-Cal program.

MCPs must have a process to determine the type of palliative care medically necessary or reasonable for eligible beneficiaries. MCPs must have an adequate network of palliative care providers to meet the need of their beneficiaries.

Additionally, MCPs may authorize additional palliative care that is not described above, at the MCP's discretion and cost. An example of an additional service that is offered by many community-based palliative care programs is a telephonic palliative care support line, separate from a routine advice line that is available twenty-four hours a day, seven days a week.

ill. Providers

MCPs may authorize palliative care to be provided in a variety of settings, including but not limited to: inpatient, outpatient, or community-based settings. MCPs must utilize qualified providers for palliative care based on the setting and needs of a beneficiary so long as the MCP ensures that its providers comply with existing Medical contracts and/or APLs. DHCS recommends that MCPs use providers with current palliative care training and/or certification to conduct palliative care consultations or assessments.

MCPs may contract with hospitals, long-term care facilities, clinics, hospice agencies, home health agencies, and other types of community-based providers that include licensed clinical staff. MCPs may contract with different types of providers depending on local provider qualifications and the need to reflect the diversity of their membership. Community-Based Adult Services (CBAS) facilities may be considered as a palliative care partner for facilitating advance care planning or palliative care referrals. Palliative care provided in a beneficiary's home must comply with existing Medi-Cal requirements for in-home providers, services, and authorization, such as physician assessments and care plans.

IV. MCP Policies and Procedures

MCPs must update their written Policy and Procedures (P&Ps) for palliative care and Evidence of Coverage (EOC) documents as outlined in this APL. MCPs shall submit their updated P&Ps and revised EOC to the DHCS contract manager on or before March 1, 2017.

¹³ APL "Medi-Cal Managed Care Plan Responsibilities For OUtpatinet Mental Health Services" available at: http://www.dhcs.ca.gov/formsandpubs/Documents/MMCDAPLsandPolicyLetters/APL2013/APL13-021.pdf

The MCPs' P&Ps for palliative care must describe:

- The process the MCP will utilize to inform and educate providers regarding the availability of palliative care;
- 2. The eligibility criteria for providers to identify beneficiaries eligible for palliative care and include a provider referral process;
- The process the MCP will utilize to address disputes related to the provision of palliative care consistent with current grievance and appeals requirements;
- 4. The method the MCP will utilize to monitor and collect palliative care enrollment and utilization data. The MCP must report palliative care data to DHCS on a quarterly basis and upon request.

MCPs are responsible for ensuring that their delegates comply with all applicable state and federal law and regulations and other contract requirements as well as DHCS's guidance, including APLs and Dual Rlan Letters. DHCS's readiness review process includes a review of each MCP's delegation oversight. MCP's must receive prior approval from DHCS for each delegate.

If you have any questions regarding this ARL, please contact your Contract Manager.

Sincerely,

Nathan Nau, Chief Managed Care Quality and Monitoring Division Department of Health Gare Services

Attachment A: Palliative Care Resources

DHCS SB 1004 Palliative Care Website: Materials available related to SB 1004. Please send questions to: SB1004@dhcs.ca.gov

California HealthCare Foundation (CHCF): Wide range of online materials and resources, as well as in-person technical assistance events.

<u>Coalition for Compassionate Care of California:</u> Consumer and provider resources on advance care planning and palliative care. Also frequent webinars and training programs.

California State University Institute for Palliative Care: Instructor-led and self-paced online training for health care professionals as well as for patients and families.



Santa Clara Family Health Plan Top 10 Drugs by Total Cost Fill date: 10/1/2016 – 12/31/2016

SAC01 - Medi-Cal

	AND THE PARTY OF T									A 100000 10 10	
	Label Name	Total Cost	Patient Paid	Plan Pald	% of Total Plan Pald	Generic % of Plan Paid	Total Claims	% of Total Claims	Generic % of Total Claims	Plan Paid / Day	Plan Paid : Claim
1	FPCLUSA 400 MG-100 MG TABLET	\$2,421,191	\$0.00	\$2,421,191	8.1%	0.0%	194	0.093	80.0	\$891.45	\$12,480.3
2	ZEPATIER 50-100 MG TABLET	\$1,251,969	\$0.00	\$1,251,969	4.2%	0.0%	138-	0.0%	0.0%	\$548.02	\$9,072.24
3	HUMRA 40 MG/0,8 ML PEN	5995,025	30,00	\$995,025	3.2%	0.0%	221	0.0%	8.0%	\$160.85	\$4,502.33
4	FREESTYLE LITE TEST STRIP	3940,150	\$0.00	\$940,150	3.1%	0.0%	3,771	1.7%	0.0%	33.92	\$107.19
5	LANTUS SOLOSTAR 100 UNITS/ML	\$663,862	\$0,00	3663,555	2.2%	0.0%	1,463	0.3%	0.0%	99.85	\$392.12
ė.	HUMALOG 100 UNITS/ML YIAL	\$603,125	90.00	\$609,133	2.0%	0.035	1,476	0.3%	0.0%	\$15.71	\$412.05
7	RENAGEL NOO MG TARLET	3575,021	30,00	\$575,021	1.9%	0.0%	314	0.1%	0.0%	\$63.57	\$1,831.2
8	LANTUS 100 UNITS/ML VIAL	\$556,063	\$0,00	\$566,063	1.93	0.0%	1,861	0.491	0.0%	\$11.57	\$304,12
9	YENTOLIN HEA 90 MCG NHALER	3501,439	\$0.00	5501,441	1.7%	0.0%	9,139	1.8%	0.0%	\$2.58	\$54.87
10	QVAR 80 MCG ORAL INHALER	\$443,402	50.00	\$443,402	1.5%	0.0%	2,127	0.4%	0.0%	\$7.07	\$206,46
Totals	for Top 10	\$4,966,310	50.00	\$8,966,316	30,0%	0.0%	25,934	5.0%	0.0%	513.35	5345.74
Totals	for SAC	529,917,484	50.00	529,917,482	100:0%	2816%	515,805	100,0%	BBLBN	51.91	\$58.00

SAC02 - Healthy Kids

	Label Rame	Total Cost	Patient Paid	Plan Paid	% of Total Plan Paid	Generic % of Plan Paid	Total Claims	% of Total Claims	Generic % of Total Claims	Plen Paid / Day	Plan Paid / Claim
1	HUMALOG 100 UNITS/ML VIAL	\$3,101	\$80	\$3,021	10.1%	0.6%	8	1.0%	0.0%	\$20.01	\$377.65
2	EPIPEN JR 2-PAK 0.15 MG INJCTR	\$2,456	\$40	\$2,426	8.1%	0.0%	4	0.58	0.29	\$63.85	\$606.3!
3	VENTOLIN HEA 90 MCG INHALER	\$2,440	\$405	\$2,035	6.3%	0.098	45	5.4%	0.0%	52.17	\$45.2
4	EPIPEN 2-PAK 0.3 MG AUTO- INJET	\$1,915	\$25	\$1,890	ć. 366	0.0%	3	0.4%	0.0%	\$29.08	\$630.00
5	QVAR BO MCG ORAL INHALER	\$1,813	\$80	\$1,733	5.3%	0.0%	9	1.2%	0.0%	\$6,22	5192.33
¥4	TRIJVADA 200 MG-300 MG TABLET	\$1,484	\$5	\$1,479	4.9%	0.0%	í	0.1%	9.0%	549.29	\$1,478.97
7	CLINDAMYCHI PH 18 GEL	\$1,114	980	\$1,034	3.4%	100.0%	8	1.05	100,038	34.92	\$129.20
43	OVAR 40 MCG ORAL INHALER	\$1,072	\$60	\$1,012	3,4%	0.0%	7	0.9%	0.0%	54.82	\$144.60
7)	BUDESONIDE 0.5 MG/2 ML SUSP	3759	\$20	5749	2.5%	100.0%	2	0.3%	100.0%	\$16.64	\$374.40
10	CLINDAMYCIN PH 1% SOLUTION	\$747	3110	\$637	2.1%	100.0%	12	1.6%	100.0%	\$2.12	\$53.06
Totals	for Top 10	\$16,920	\$905	516,015	53.4M	15, 188	99	13.0%	22.2%	\$7.09	\$161.77
Totals	s for SAC	536,278	\$6,203	529,995	100.0%	51.75	762	100.0%	85.4%	52,04	539.36

SAC06 - Cal MediConnect

	Label Name	Total Cost	Patient Pard	Plen Fels	% of Total Plan Paid	Ganario % of Plan Paid	Total Claims	% of Total Claims	Generic Not Testi Claims	Plan Paid / Day	Plan Pale / Claim
1	HARVONI 90-400 MG TABLET	5535,622	\$0.00	\$835,612	6.4%	0.08	17	0.0%	0.0%	\$1,125,26	\$31,507,20
2	EPCLISA 400 MG-100 MG TABLET	\$200,888	\$0.00	\$200,868	2.4%	0.0%	8	0.0%	0.0%	\$895.82	525,111.04
4	FREISTALL LITE TEST STRIP	\$173,220	50.00	\$173,230	2.5%	0.0%	1,582	2.6%	0.0%	\$3.76	\$109.36
4	LANTUS 100 UNITS/ML VIAL	\$143,346	975	\$143,171	1.7%	0.0%	369	0.5%	0,000	\$11.90	\$385,00
5	INVEGA SUSTENNA 234 MG/1.5	\$125,766	\$0.00	\$135,766	1.8%	0.0%	61	0.1%	0.0%	380.86	\$2,225.60
ó	LANTUS SOLOSTAR 100 UNITS/AIL	9124,154	513	5124,141	1.5%	0.00	389	0.5%	0.0%	\$9.29	\$349.69
7	SPIRIVA 18 MCG CP- HANDIHAL FR	5121,432	9143	5125,250	1.4%	0.0%	278	0.4%	0.0%	\$11.42	\$435.29
3	JANUVIA 100 MG TABLET	5113,717	\$110	\$113,668	1.42.	0.0%	204	0.32	0.0%	\$11.84	\$551,49
*)	ENBREL 50 MG/HL SYRINGE	5106,027	\$0,90	\$105,027	1.3%	0.0%	22	0.03	0.0%	\$143,64	\$4,519,43
10	NOVOLOG 100 LINITS/AK.	5103,970	50,00	5103,970	1.2%	0.0%	175	9.2%	0.0%	\$19.50	\$594.11
Totals	for Top 10	\$1,750,154	\$342	\$1,757,812	20,9%	0.0%	1,073	4,0%	0.0%	516.40	5577.62
Totali	for SAC	\$8,413,211	\$1,239	\$8,411,978	100,0%	24:2%	77,326	100,0%	83.0%	52.54	\$108.79

Santa Clara Family Health Plan Top 10 Drugs Requested for Prior Authorization

PA Finalized Date Range: 10/1/2016 – 12/31/2016

SAC01 - Medi-Cal

Rank	Drug Category	PA Count Finalized	PA Count Approved	PA Count Denied / Partial Approved	PA Count Other	PA Approved %	Rx Count	Total Amt Paid	Ami Pald/Rx
1	NUMALOG 100 UNITS/ML KWIKPEN	202	149	20	33	73.76%	545	\$334,671.52	\$614.08
2	FREESTYLE LITE TEST	126	123	1	2	97.62%	229	363,484.50	\$233.43
3	ASPIREN EC 81 MG TABLET	100	100	Ō	0	100,009	101	\$375,15	\$3.72
4	XARELTO 20 MG TABLET	95	59	22	14	62,11%	163	\$62,883.89	\$374.31
5	DICLOFENAC SODIUM 1% GEL	90	36	50	4	40.00%	72	\$4,422.52	\$61.43
6	LANTUS 100 UNITS/ML VIAL	83	79	9	4	95.18%	443	\$190,862.50	\$426.03
7	RESTASIS 0.05% EYE EMULSION	52	29	39	14	35.37%	126	352,574.71	\$417.26
8	HUMIRA 40 MG/0.8 ML PEN	73	51	13	9	69.86%	221	\$995,024.69	\$4,502.37
9	TRETINOIN 0.025% CREAM	5ó	27	23	16	40.91%	38	\$5,930.68	\$155.07
10	ANLODIPINE SESYLATE 5 MG TAB	60	55	5	9	91,67%	71	5442.20	\$6.23
Votals	for Top 10	977	708	173	96	72.47%	2,019	\$1,700,443,77	\$842,37
Totals	for SAC	6,201	5,494	1,814	195	66.98%	14,379	\$15,796,093.33	\$1,098.55

SAC02 - Healthy Kids

Rank	Drug Category	PA Count Finalized	PA Count Approved	PA Court Denied / Partial Approved	PA Count Other	Approved %	Rx Count	Total Amt	Amt Paid/Rx
1	FLUARIX QUAD 2016-2017 SYRINGE	2	2	D	0	100,00%	0	\$0.00	50.00
2	METHYLPHENIDATE ER 27 MG TAB	2	0	2	0	0.00%	0	\$0.00	\$0.00
3	TRETINOIN 0.025% CREAM	2	0	0	2	0.00%	0	\$0.00	50.00
4	VESICARE 10 MG TABLET	2		0	1	50.00%	1	\$263,21	\$283.21
5	DEXTROAMPHETAMINE 10 MG TAB	4	1	0	0	100.00%	2	\$259.04	\$134,52
6	ELIDEL 1% CREAM	1	0	3	0	0.00%	0	\$0.00	\$0.00
7	EPIPEN 2-PAK 0.3 MG AUTO-INJCT	- 0	1	0	٥	100.00%	0	\$0,00	\$0,00
8	METHYLPHENIDATE 10 MG/5 ML SOL	t	1	0	0	100.00%	1	\$158,32	\$158,32
9	MONTELUKAST 500 4 MG GRANULES	1	0	1	a	0.00%	0	\$0.00	50.00
10	TACROLIMUS 0.1% OINTMENT	í	D	1	0	0.00%	0	\$0,00	\$0.00
Totals	for Top 10	54	- 6	1	3	42.86%	4	\$710.57	\$177.64
Totals	for SAC	14	6	5	3	42.86%	B	\$1,750,67	\$219.58

SAC06 - Cal MediConnect

Rank	Drug Category	PA Count Finalized	PA Count Approved	PA Count Denied / Partial Approved	PA Count Other	Approved %	Rx Count	Total Ame Fald	Amt Paid/Rx
1	LIDOCAINE 5% PATCH	36	19	9	3	52.78%	30	\$6,599.45	\$219.90
2	ZOLPIDEM TARTRATE 5 MG TABLET	16	10	3	3	62.50%	81	\$379,61	56.23
3	ZOLPIDEM TARTRATE 10 MG TABLET	14	žķ.	3	2	64.29%	37	\$209.85	\$5.66
d	BENZTROPINE MES 1 MG TABLET	5	3	3	2	37.50%	18	\$193.40	\$10.74
5	HYDROCHLOROTHIAZIDE 25 MG TAB	8	83	٥	0	100.00%	7	\$27,46	53.92
6	OMEPRAZOLE DR 20 MG CAPSULE	7	y	Û	Q.	100.00%	6	\$67.64	\$11.27
7	AMLODIPINE BESYLATE 5 MG TAB	6	6	0	0	100.00%	6	\$33.76	\$5.63
8	GLIPIZIDE 5 MG TABLET	W	6	0	0	100.00%	19	\$140.50	\$7.41
9	HYDROXYZINE MCL 10 MG TABLET	its	4	1	Y	66.67%	8	\$106.34	\$13.29
10	LOSARTAN POTASSIUM 50 MG TAB	6	6	0	0	100.00%	5	\$43.76	\$8.75
Totals	for Tep 10	113	78	19	16	69.93N	197	\$7,861.99	\$39.60
Totals	for SAC	641	515	77	54	80,34%	1,701	\$2,275,515.59	\$1,337,75



The Spirit of Care

CONFIDENTIALITY, CONFLICT OF INTEREST & NON-DISCRIMINATION AGREEMENT 2017

CONFIDENTIALITY STATEMENT

I understand that Santa Clara Family Health Plan (SCFHP) has a legal and ethical responsibility to comply with all applicable federal and state laws established under the Health Insurance Portability and Accountability Act (HIPAA) and Privacy Rule adopted thereunder (45 CFR Parts 160 and 164) and all related SCFHP Policies and Procedures.

In addition, I understand that during the course of my affiliation with the Provider Advisory Council (PAC), I agree to respect and maintain the confidentiality of all confidential information, especially Protected Health Information (PHI). I also agree that my obligations under this agreement regarding PHI will continue after the termination of my affiliation with the PAC.

CONFLICT OF INTEREST STATEMENT

I understand and agree that I will report to the Committee Chairperson if I have a financial or non-financial conflict of interest which would impair my objectivity in performing my responsibilities as a member of the PAC. Furthermore, I will refrain from any proceeding or cast a vote on any issue related to conflict of interest.

NON-DISCRIMINATION

Santa Clara Family Health Plan (SCFHP) and all PAC Committee Members comply with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, religion, citizenship status, genetic information, marital status, sexual orientation and identity, medical condition, AIDS/HIV, military or veteran status, political affiliations or activities, or status as a victim of domestic violence, assault or stalking.

AGREEMENT

Print Name

I, th	ne i	unde	ersig	gned,	have	read	and	unde	rstand	d the	above	Con	fiden	tiality	and	Confl	ict of	Inter	est S	Staten	nent
and	ag	gree	to	abide	by	these	stan	dards	and	requi	rements	s in	the	condu	ict of	my	respo	onsibi	lities	relate	ed to
mat	tter	s of	the	PAC.																	

Signature	Date